TWI561514B - Apoptosis signal-regulating kinase inhibitor - Google Patents

Apoptosis signal-regulating kinase inhibitor

Info

Publication number
TWI561514B
TWI561514B TW103125752A TW103125752A TWI561514B TW I561514 B TWI561514 B TW I561514B TW 103125752 A TW103125752 A TW 103125752A TW 103125752 A TW103125752 A TW 103125752A TW I561514 B TWI561514 B TW I561514B
Authority
TW
Taiwan
Prior art keywords
kinase inhibitor
apoptosis signal
regulating kinase
regulating
apoptosis
Prior art date
Application number
TW103125752A
Other languages
English (en)
Other versions
TW201441213A (zh
Inventor
Gregory Notte
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of TW201441213A publication Critical patent/TW201441213A/zh
Application granted granted Critical
Publication of TWI561514B publication Critical patent/TWI561514B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW103125752A 2012-01-27 2013-01-25 Apoptosis signal-regulating kinase inhibitor TWI561514B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261591710P 2012-01-27 2012-01-27

Publications (2)

Publication Number Publication Date
TW201441213A TW201441213A (zh) 2014-11-01
TWI561514B true TWI561514B (en) 2016-12-11

Family

ID=47684038

Family Applications (4)

Application Number Title Priority Date Filing Date
TW105128669A TWI634890B (zh) 2012-01-27 2013-01-25 細胞凋亡訊號調節激酶之抑制劑
TW103125752A TWI561514B (en) 2012-01-27 2013-01-25 Apoptosis signal-regulating kinase inhibitor
TW107127139A TW201916877A (zh) 2012-01-27 2013-01-25 細胞凋亡訊號調節激酶之抑制劑
TW102102991A TWI487523B (zh) 2012-01-27 2013-01-25 細胞凋亡訊號調節激酶之抑制劑

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW105128669A TWI634890B (zh) 2012-01-27 2013-01-25 細胞凋亡訊號調節激酶之抑制劑

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW107127139A TW201916877A (zh) 2012-01-27 2013-01-25 細胞凋亡訊號調節激酶之抑制劑
TW102102991A TWI487523B (zh) 2012-01-27 2013-01-25 細胞凋亡訊號調節激酶之抑制劑

Country Status (40)

Country Link
US (7) US8742126B2 (zh)
EP (1) EP2807151B1 (zh)
JP (1) JP5770950B2 (zh)
KR (5) KR20170128622A (zh)
CN (2) CN109438418B (zh)
AP (1) AP2014007836A0 (zh)
AR (2) AR089818A1 (zh)
AU (1) AU2013201586C1 (zh)
BR (1) BR112014018355B1 (zh)
CA (3) CA3026700C (zh)
CL (1) CL2014001988A1 (zh)
CO (1) CO7061073A2 (zh)
CR (1) CR20140405A (zh)
CY (1) CY1117201T1 (zh)
DK (1) DK2807151T3 (zh)
EA (1) EA024746B1 (zh)
ES (1) ES2558203T3 (zh)
HK (1) HK1204324A1 (zh)
HR (1) HRP20151399T1 (zh)
HU (1) HUE028641T2 (zh)
IL (3) IL233598A (zh)
IN (1) IN2014DN06174A (zh)
MA (1) MA35861B1 (zh)
MD (1) MD4601B1 (zh)
ME (1) ME02322B (zh)
MX (3) MX2014009075A (zh)
NZ (1) NZ739339A (zh)
PE (1) PE20141822A1 (zh)
PH (1) PH12014501697A1 (zh)
PL (1) PL2807151T3 (zh)
PT (1) PT2807151E (zh)
RS (1) RS54492B1 (zh)
SG (1) SG11201404348UA (zh)
SI (1) SI2807151T1 (zh)
SM (1) SMT201600047B (zh)
TW (4) TWI634890B (zh)
UA (1) UA112098C2 (zh)
UY (1) UY34573A (zh)
WO (1) WO2013112741A1 (zh)
ZA (1) ZA201405260B (zh)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
PL2651417T3 (pl) 2010-12-16 2017-08-31 Calchan Limited Pochodne pirolopirymidyny hamujące ASK1
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
CA2931615A1 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
JP2017503001A (ja) 2014-01-20 2017-01-26 ギリアード サイエンシーズ， インコーポレイテッド がんを処置するための療法
WO2015187499A1 (en) 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
TW201618781A (zh) * 2014-08-13 2016-06-01 吉李德科學股份有限公司 治療肺高血壓之方法
MX2017003933A (es) * 2014-09-24 2017-06-30 Gilead Sciences Inc Metodos de tratamiento de la enfermedad hepatica.
US9586933B2 (en) * 2014-12-23 2017-03-07 Gilead Sciences, Inc. Processes for preparing ASK1 inhibitors
MA41252A (fr) * 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
DK3321265T3 (da) 2015-03-04 2020-06-08 Gilead Sciences Inc 4,6-diamino-pyrido[3,2-d]pyrimidinforbindelser og deres udnyttelse som modulatorer af toll-lignende receptorer
IL293770B2 (en) 2015-07-06 2023-07-01 Gilead Sciences Inc Modulators of cot and methods of using them
ES2900482T3 (es) 2015-10-01 2022-03-17 Gilead Sciences Inc Combinación de un inhibidor de Btk y un inhibidor de punto de control para el tratamiento del cáncer
MX2018007421A (es) 2015-12-17 2018-08-15 Gilead Sciences Inc Compuestos inhibidores de quinasa de union a tank.
JP2019510752A (ja) 2016-03-04 2019-04-18 ギリアード サイエンシーズ， インコーポレイテッド オートタキシン阻害剤の組成物及び合剤
EP3440113A1 (en) 2016-04-08 2019-02-13 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
KR101996019B1 (ko) 2016-06-13 2019-07-03 아이-맵 항-pd-l1 항체 및 이것의 사용
EP3493797A1 (en) 2016-08-04 2019-06-12 Gilead Sciences, Inc. Cobicistat for use in cancer treatments
MA46093A (fr) 2016-09-02 2021-05-19 Gilead Sciences Inc Composés modulateurs du recepteur de type toll
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
US20180133212A1 (en) 2016-11-03 2018-05-17 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
JP2019533706A (ja) 2016-11-11 2019-11-21 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置する方法
US20180141939A1 (en) 2016-11-22 2018-05-24 Gilead Sciences, Inc. Solid forms of a bet inhibitor
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10787435B2 (en) 2017-01-22 2020-09-29 Fuijan Cosunter Pharmaceutical Co. Ltd. ASK1 inhibitor and preparation method and use thereof
SG11201906579UA (en) * 2017-01-22 2019-08-27 Fujian Cosunter Pharmaceutical Co Ltd Pyridine derivative as ask1 inhibitor and preparation method and use thereof
PE20191208A1 (es) 2017-01-24 2019-09-10 I Mab Anticuerpos anti-cd73 y usos de los mismos
TWI754011B (zh) 2017-02-24 2022-02-01 美商基利科學股份有限公司 布魯頓氏酪胺酸激酶之抑制劑
WO2018156901A1 (en) 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
WO2018157277A1 (en) 2017-02-28 2018-09-07 Eli Lilly And Company Isoquinolin and naphthydrin compounds
CN109983007B (zh) * 2017-03-03 2021-11-05 江苏豪森药业集团有限公司 酰胺类衍生物抑制剂及其制备方法和应用
JOP20180017A1 (ar) 2017-03-14 2019-01-30 Gilead Sciences Inc مثبط كيناز منظم لإشارة تلاشي خلايا
CN110475556A (zh) 2017-03-28 2019-11-19 吉利德科学公司 治疗肝疾病的方法
CN110520125A (zh) 2017-04-12 2019-11-29 吉利德科学公司 治疗肝病的方法
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
US10683279B2 (en) 2017-05-12 2020-06-16 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218051A1 (en) * 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10246439B2 (en) 2017-05-25 2019-04-02 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218042A1 (en) * 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018231851A1 (en) 2017-06-13 2018-12-20 Gilead Sciences, Inc. Methods of treating liver fibrosis
TW201908306A (zh) * 2017-07-18 2019-03-01 大陸商南京聖和藥業股份有限公司 作為ask抑制劑的雜環化合物及其應用
WO2019046186A1 (en) 2017-08-28 2019-03-07 Enanta Pharmaceuticals, Inc. INHIBITORS OF KINASE 1 REGULATING THE APOPTOTIC SIGNAL CONTAINING TETRAZOLES AND METHODS OF USE THEREOF
CN109456308B (zh) * 2017-09-06 2022-11-29 南京圣和药业股份有限公司 作为ask抑制剂的杂环化合物及其应用
WO2019047094A1 (en) * 2017-09-07 2019-03-14 Eli Lilly And Company CYCLOBUTYL-IMIDAZOLIDINONE COMPOUNDS
US10370352B2 (en) 2017-09-07 2019-08-06 Eli Lilly And Company Cyclobutyl-imidazolidinone compounds
WO2019047161A1 (en) * 2017-09-08 2019-03-14 Eli Lilly And Company IMIDAZOLIDINE COMPOUNDS
EP3678662A4 (en) 2017-09-08 2021-09-01 Fronthera U.S. Pharmaceuticals LLC APOPTOSIS SIGNAL REGULATION KINASE INHIBITORS AND THEIR USES
WO2019072130A1 (zh) * 2017-10-12 2019-04-18 深圳市塔吉瑞生物医药有限公司 一种1,2,4-三氮唑类化合物
CN107793400B (zh) * 2017-10-31 2020-01-31 武汉九州钰民医药科技有限公司 吡啶类化合物及其在制备治疗肝脏疾病的药物中的应用
US20200340060A1 (en) 2017-11-13 2020-10-29 Gilead Sciences, Inc. Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes
KR102492187B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
JP7098748B2 (ja) 2017-12-20 2022-07-11 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド
EP3735404B1 (en) 2018-01-02 2023-11-29 Seal Rock Therapeutics, Inc. Ask1 inhibitor compounds and uses thereof
ES2949664T3 (es) 2018-02-13 2023-10-02 Gilead Sciences Inc Inhibidores PD-1/PD-L1
CN110294742B (zh) * 2018-03-21 2023-01-31 山东轩竹医药科技有限公司 并环类ask1抑制剂及其应用
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202012414A (zh) 2018-04-12 2020-04-01 美商拓臻股份有限公司 三環ask1抑制劑
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CN110407806B (zh) * 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 甲酰胺类化合物、其制备方法及其应用
US10683289B2 (en) 2018-05-02 2020-06-16 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN112312905B (zh) 2018-05-02 2024-03-15 英安塔制药有限公司 含四唑的细胞凋亡信号调节激酶1抑制剂及其使用方法
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
EP3814272A4 (en) 2018-05-11 2022-03-02 Phosphorex, Inc. MICROPARTICLES AND NANOPARTICLES WITH NEGATIVE SURFACE CHARGES
HUE057852T2 (hu) 2018-05-14 2022-06-28 Gilead Sciences Inc MCL-1 inhibítorok
WO2020006429A1 (en) * 2018-06-28 2020-01-02 Hepatikos Therapeutics, Llc Ask1 isoindolin-1-one inhibitors and methods of use thereof
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
CN112638912B (zh) * 2018-07-20 2022-04-26 福建广生中霖生物科技有限公司 作为ask1抑制剂的晶型及其制备方法和应用
US10968199B2 (en) 2018-08-22 2021-04-06 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
KR102298546B1 (ko) * 2018-10-18 2021-09-08 에이치케이이노엔 주식회사 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
FI3873903T3 (fi) 2018-10-31 2024-03-26 Gilead Sciences Inc Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
CA3116347A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
CN111170995A (zh) * 2018-11-09 2020-05-19 山东轩竹医药科技有限公司 Ask1抑制剂及其应用
US11345699B2 (en) 2018-11-19 2022-05-31 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN109608441A (zh) * 2018-12-26 2019-04-12 都创(上海)医药科技有限公司 一种ask1抑制剂的合成工艺
EA202191566A1 (ru) 2019-01-15 2021-11-01 Джилид Сайенсиз, Инк. Соединения, модулирующие fxr (nr1h4)
CN109813915A (zh) * 2019-02-15 2019-05-28 浠思（上海）生物技术有限公司 利用htrf一步法筛选激酶抑制剂的方法
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
CN113543851A (zh) 2019-03-07 2021-10-22 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
AU2020231115A1 (en) 2019-03-07 2021-08-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
AU2020234929B2 (en) 2019-03-11 2023-09-14 Gilead Sciences, Inc. Formulations of a compound and uses thereof
US11466033B2 (en) 2019-03-25 2022-10-11 Enanta Pharmaceuticals, Inc. Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CA3140708A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
CN114245807A (zh) 2019-06-25 2022-03-25 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
US20220332700A1 (en) * 2019-06-26 2022-10-20 Mankind Pharma Ltd Novel apoptosis signal-regulating kinase 1 inhibitors
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
CA3208912A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
KR20220101137A (ko) 2019-11-15 2022-07-19 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
CN111018831B (zh) * 2019-11-21 2022-05-31 中国药科大学 细胞凋亡信号调节激酶抑制剂及其应用
US20230105984A1 (en) 2019-12-23 2023-04-06 Svetlana Marukian Compositions and methods for the treatment of liver diseases and disorders
AU2020412875A1 (en) 2019-12-24 2022-06-23 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
CA3169451A1 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
JP2023520650A (ja) 2020-03-30 2023-05-18 ギリアード サイエンシーズ， インコーポレイテッド （Ｓ）－６－（（（１－（ビシクロ［１．１．１］ペンタン－１－イル）－１Ｈ－１，２，３－トリアゾール－４－イル）２－メチル－１－オキソ－１，２－ジヒドロイソキノリン－５－イル）メチル）））アミノ）８－クロロ－（ネオペンチルアミノ）キノリン－３－カルボニトリルＣｏｔ阻害剤化合物の固体形態
JP7446475B2 (ja) 2020-04-02 2024-03-08 ギリアード サイエンシーズ， インコーポレイテッド Ｃｏｔ阻害剤化合物を調製するためのプロセス
JP2023524074A (ja) 2020-05-01 2023-06-08 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
WO2021247215A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
CN111808079A (zh) * 2020-08-05 2020-10-23 中国药科大学 吲哚类ask1小分子抑制剂及其制备方法和应用
CN114470217B (zh) * 2020-11-24 2023-06-20 深圳微芯生物科技股份有限公司 预防和治疗代谢异常或炎症引起的组织损伤的药物组合物
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
AU2022252182A1 (en) 2021-03-29 2023-09-28 Gilead Sciences, Inc. Khk inhibitors
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
CN114246866B (zh) * 2021-04-28 2023-09-12 深圳微芯生物科技股份有限公司 用于治疗慢性肾病的药物及其用途
AU2022273631A1 (en) 2021-05-11 2023-11-02 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
US20220411406A1 (en) 2021-05-13 2022-12-29 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022299051A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240091056A (ko) 2021-10-28 2024-06-21 길리애드 사이언시즈, 인코포레이티드 피리디진-3(2h)-온 유도체
AU2022376954A1 (en) 2021-10-29 2024-05-02 Gilead Sciences, Inc. Cd73 compounds
AU2022405082A1 (en) 2021-12-08 2024-07-11 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
AU2022419982A1 (en) 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
US20240254118A1 (en) 2022-12-22 2024-08-01 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN115844887B (zh) * 2022-12-28 2023-09-08 中国人民解放军空军军医大学 Selonsertib在制备治疗癌症的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009410A1 (en) * 2009-07-13 2011-01-13 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159731A (en) 1997-02-12 2000-12-12 Massachusetts Institute Of Technology Daxx, a Fas-binding protein that activates JNK and apoptosis
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
AU782448B2 (en) 1999-03-19 2005-07-28 Aventis Pharmaceuticals Inc. Akt nucleic acids, polypeptides, and uses thereof
AU2001275330A1 (en) * 2000-06-07 2001-12-17 Marc D. Andelman Fluid and electrical connected flow-through electrochemical cells, system and method
US20070237770A1 (en) 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
US20070167386A1 (en) 2003-07-28 2007-07-19 Osaka Industrial Promotion Organization Remedy for cardiac failure containing ask1 inhibitor as active ingredient and method for screening the same
JP2008514635A (ja) 2004-09-27 2008-05-08 コーザン バイオサイエンシス インコーポレイテッド 特異的キナーゼ阻害剤
US7696202B2 (en) 2004-11-10 2010-04-13 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
EP1677113A1 (en) 2004-12-29 2006-07-05 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Method for the identification of protein-protein interactions in disease related protein networks
US20070276050A1 (en) 2006-02-27 2007-11-29 Gilead Sciences, Inc. Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases
JPWO2008016131A1 (ja) 2006-08-04 2009-12-24 武田薬品工業株式会社 縮合複素環化合物
WO2008042867A2 (en) 2006-09-29 2008-04-10 Emiliem Inc. Modulators of multiple kinases
WO2008073919A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
US8104727B2 (en) 2007-03-12 2012-01-31 Denis Joanisse Adjustable article support
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
WO2009027283A1 (en) 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
WO2009123986A1 (en) 2008-03-31 2009-10-08 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
WO2010008843A1 (en) 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
US20110263441A1 (en) 2008-10-15 2011-10-27 Golub Todd R Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders
US20110294693A1 (en) 2008-11-17 2011-12-01 The George Washington University Compositions and Methods for Identifying Autism Spectrum Disorders
JP2012521760A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
PL2531501T3 (pl) 2010-02-03 2014-05-30 Takeda Pharmaceuticals Co Inhibitory kinazy 1 regulującej sygnał apoptotyczny
JP2013518909A (ja) 2010-02-08 2013-05-23 キナゲン，インク． アロステリックキナーゼ阻害が関係する治療方法および組成物
MX345552B (es) 2010-03-24 2017-02-02 Amitech Therapeutic Solutions Inc Compuestos heterocíclicos útiles para inhibición de cinasa.
EA023040B1 (ru) 2010-07-02 2016-04-29 Джилид Сайэнс, Инк. Ингибиторы киназ, регулирующих апоптозный сигнал
US20130236441A1 (en) 2010-11-18 2013-09-12 University Of Delaware Methods of treating and preventing thrombotic diseases using ask1 inhibitors
PL2651417T3 (pl) 2010-12-16 2017-08-31 Calchan Limited Pochodne pirolopirymidyny hamujące ASK1
JP2014507160A (ja) 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
BR112013031591A2 (pt) 2011-06-07 2016-12-13 Caris Life Sciences Luxembourg Holdings S A R L biomarcadores de circulação para câncer
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
US8924765B2 (en) 2011-07-03 2014-12-30 Ambiq Micro, Inc. Method and apparatus for low jitter distributed clock calibration
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
US9586933B2 (en) 2014-12-23 2017-03-07 Gilead Sciences, Inc. Processes for preparing ASK1 inhibitors
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009410A1 (en) * 2009-07-13 2011-01-13 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors

Also Published As

Publication number Publication date
MX2014009075A (es) 2014-09-01
KR20170128622A (ko) 2017-11-22
AU2013201586C1 (en) 2015-06-18
TWI634890B (zh) 2018-09-11
SI2807151T1 (sl) 2016-08-31
UA112098C2 (uk) 2016-07-25
TW201916877A (zh) 2019-05-01
IL257965A (en) 2018-05-31
CN104080771B (zh) 2018-11-09
HRP20151399T1 (hr) 2016-01-29
KR101799739B1 (ko) 2017-11-20
AR117113A2 (es) 2021-07-14
CA3026700A1 (en) 2013-08-01
SMT201600047B (it) 2016-02-25
TW201334782A (zh) 2013-09-01
ME02322B (me) 2016-06-20
UY34573A (es) 2013-06-28
CN104080771A (zh) 2014-10-01
AP2014007836A0 (en) 2014-07-31
CA2862030C (en) 2019-10-29
DK2807151T3 (en) 2016-02-22
ZA201405260B (en) 2016-05-25
JP5770950B2 (ja) 2015-08-26
IL233598A (en) 2015-06-30
HUE028641T2 (en) 2016-12-28
CA3026738A1 (en) 2013-08-01
EA201491283A1 (ru) 2014-12-30
MX365954B (es) 2019-06-20
US20190248762A1 (en) 2019-08-15
CN109438418A (zh) 2019-03-08
KR101707764B1 (ko) 2017-02-16
SG11201404348UA (en) 2014-08-28
KR20160004401A (ko) 2016-01-12
US9333197B2 (en) 2016-05-10
US20170217933A1 (en) 2017-08-03
IN2014DN06174A (zh) 2015-08-21
US9254284B2 (en) 2016-02-09
CA3026738C (en) 2020-12-15
EA024746B1 (ru) 2016-10-31
BR112014018355A2 (zh) 2017-06-20
CL2014001988A1 (es) 2014-11-03
RS54492B1 (en) 2016-06-30
IL233598A0 (en) 2014-08-31
CA3026700C (en) 2020-12-15
ES2558203T3 (es) 2016-02-02
CR20140405A (es) 2014-11-27
MX2019007348A (es) 2019-09-05
US20160235728A1 (en) 2016-08-18
US20140228411A1 (en) 2014-08-14
TWI487523B (zh) 2015-06-11
MA35861B1 (fr) 2014-12-01
KR20140117609A (ko) 2014-10-07
MD20140082A2 (ro) 2015-01-31
JP2015508749A (ja) 2015-03-23
KR20170018474A (ko) 2017-02-17
PL2807151T3 (pl) 2016-05-31
CA2862030A1 (en) 2013-08-01
MD4601B1 (ro) 2018-11-30
EP2807151B1 (en) 2015-11-18
AU2013201586B2 (en) 2015-01-22
CN109438418B (zh) 2021-04-13
WO2013112741A1 (en) 2013-08-01
PH12014501697B1 (en) 2014-10-20
TW201441213A (zh) 2014-11-01
BR112014018355A8 (pt) 2017-07-11
CY1117201T1 (el) 2017-04-05
EP2807151A1 (en) 2014-12-03
PH12014501697A1 (en) 2014-10-20
BR112014018355B1 (pt) 2021-10-05
US20140228412A1 (en) 2014-08-14
KR20190000898A (ko) 2019-01-03
CO7061073A2 (es) 2014-09-19
NZ739339A (en) 2019-07-26
NZ754169A (en) 2021-01-29
KR101582065B1 (ko) 2015-12-31
US9750730B2 (en) 2017-09-05
IL239311A0 (en) 2015-07-30
AR089818A1 (es) 2014-09-17
PT2807151E (pt) 2016-01-28
AU2013201586A1 (en) 2013-08-15
PE20141822A1 (es) 2014-11-27
US20180099950A1 (en) 2018-04-12
IL239311B (en) 2018-03-29
TW201711684A (zh) 2017-04-01
US9873682B2 (en) 2018-01-23
US10508100B2 (en) 2019-12-17
US8742126B2 (en) 2014-06-03
US20130197037A1 (en) 2013-08-01
HK1204324A1 (zh) 2015-11-13

Similar Documents

Publication Publication Date Title
IL257965A (en) Apoptosis signal-regulated kinase inhibitor
IL255799B (en) Converted pyridine-2-carboxamide compounds as inhibitors of apoptosis signal-regulated kinase
IL247405A0 (en) Apoptosis signal-regulating kinase inhibitors
HK1226073A1 (zh) 凋亡信號調節激酶的抑制劑
HK1208442A1 (zh) 作為 激酶抑制劑的取代的吡咯並嘧啶基氨基－苯並噻唑酮
HK1210775A1 (zh) 作為激酶抑制劑的咪唑並三嗪甲腈
LT2892889T (lt) Inhibitoriaus junginiai
GB201211310D0 (en) CSF-1R kinase inhibitors
HK1213252A1 (zh) 雙環二氫吡啶酮激酶抑制劑
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
EP2903970A4 (en) SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
HK1213181A1 (zh) 雙環氧雜內酰胺激酶抑制劑
GB201211019D0 (en) Inhibitor compounds